Skip to main content
EJNMMI Research
Figure 2 | EJNMMI Research

Figure 2

From: Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

Figure 2

Early FDG PET response examples. (a) Trans-axial FDG PET views show left breast lesion with baseline SUV of 4.6 and follow-up SUV of 2.5 (46% decrease). Clinical response was observed after 4 months of neoadjuvant therapy + AI. (b) Coronal FDG PET views show left axillary lymph node with baseline SUV of 4.5 and follow-up SUV of 4.5 (0% change). This patient experienced progressive disease after 7 months of AI monotherapy.

Back to article page